University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 4K-12-4


A Phase II Randomized, Double-Blind, Crossover, Controlled, Multi-Center, Subject Preference Study of Tivozanib Hydrochloride versus Sunitinib in the Treatment of Subjects with Metastatic Renal Cell Carcinoma.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Kristy Sartor Massopust, Coordinator, Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.